Development of an in vitro drug screening assay using Schistosoma haematobium schistosomula

Particle and Fibre Toxicology

Jennifer Keiser¹  Katrin Ingram¹  Monika Marxer¹ 

[1] University of Basel, CH–4003, Basel, Switzerland

关键词: Biomphalaria glabrata;    Bulinus truncatus;    Percoll®;    Cercarial rhythm;    Alamar Blue®;    Newly transformed schistosomula;    Schistosoma haematobium;    Chemotherapy;    In vitro;   

Others  :  1231722
DOI  :  10.1186/1756-3305-5-165

 received in 2012-06-25, accepted in 2012-08-02,  发布年份 2012

【 摘 要 】

Background

The development of novel antischistosomal drugs is crucial, as currently no vaccine and only a single drug is available for the treatment of schistosomiasis. Fast and accurate in vitro assays are urgently needed to identify new drug candidates and research efforts should include Schistosoma haematobium. The aim of the present study was to develop a S. haematobium drug sensitivity assay based on newly transformed schistosomula (NTS).

Methods

We first undertook comparative studies on the cercarial emergence rhythms of the intermediate host snails Biomphalaria glabrata (S. mansoni) and Bulinus truncatus (S. haematobium). Two transformation methods as well as three purification methods were studied on S. haematobium cercariae in order to produce a large number of viable and clean NTS. Known antischistosomal drugs were tested in the established NTS assay in vitro. Drug effects were evaluated either microscopically or fluorometrically, using a resazurin based viability marker. Microscopically obtained IC₅₀ values were compared with results obtained for S. mansoni.

Results

A circadian rhythm existed in both snail species. Infected B. truncatus snails shed less cercariae than B. glabrata during the testing period. The highest transformation rate (69%) of S. haematobium cercariae into NTS was obtained with the vortex transformation (mechanical input) and the highest purification factor was observed using Percoll®. The fluorimetric readout based on resazurin was very precise in detecting dead or/and severely damaged schistosomula.

Conclusions

With the use of viability markers such as resazurin, drug screening assays using S. haematobium NTS can be efficiently performed. However, drugs acting on the morphology and motility of S. haematobium NTS, such as metrifonate are missed. Drug sensitivity assays with NTS of both species, S. haematobium and S. mansoni, showed very similar results using known antischistosomal drugs. The S. mansoni NTS assay might be more suitable as primary screen in drug discovery efforts, which ultimately aim for a broad-spectrum antischistosomal drug as a larger number of S. mansoni NTS can be generated.

【 授权许可】

   
2012 Marxer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

【 参考文献 】

• [1]Manson-Bahr PEC, Bell DR: Manson’s Tropical Diseases. Bailliere Tindall. 22nd edition.  ,  ; 2008.
• [2]Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J: Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006, 6:411-425.
• [3]The World Health Report 2003: shaping the future. World Health Organization, Geneva; 2003.
• [4]Gryseels B, Polman K, Clerinx J, Kestens L: Human schistosomiasis. Lancet 2006, 368:1106-1118.
• [5]Montresor A, Gabrielli AF, Chitsulo L, Ichimori K, Mariotti S, Engels D, Savioli L: Preventive chemotherapy and the fight against neglected tropical diseases. Expert Rev Anti Infect Ther 2012, 10:237-242.
• [6]Utzinger J, Keiser J: Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 2004, 5:263-285.
• [7]Chitsulo L, Engels D, Montresor A, Savioli L: The global status of schistosomiasis and its control. Acta Trop 2000, 77:41-51.
• [8]Caffrey CR: Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 2007, 11:433-439.
• [9]Keiser J: In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology 2010, 137:589-603.
• [10]Bickle QD, Mansour NR: Comparison of microscopy and Alamar Blue reduction in a larval based assay for schistosome drug screening. PLoS Negl Trop Dis 2010, 4:e795.
• [11]Ramalho-Pinto FJ, Gazinzinelli G, Howells RE, Mota-Santos TA, Figueiredo EA, Pellegrino J: Schistosoma mansoni: defined system for stepwise transformation of cercaria to schistosomule in vitro. Exp Parasitol 1974, 36:360-372.
• [12]Bash PF: Cultivation of Schistosoma mansoni in vitro. I. Establishment of cultures from cercariae and development until pairing. J Parasitol 1981, 67:179-185.
• [13]Lazdins JK, Sher A, Stein MJ, David JR: Schistosoma mansoni: rapid isolation and purification of schistosomula of different developmental stages by centrifugation on discontinuous density gradients of Percoll. Exp Parasitol 1982, 53:39-44.
• [14]Lewis F: Schistosomiasis. Curr Protoc Immunol 1999, 19:1.1-1.28.
• [15]Manneck T, Braissant O, Haggenmüller Y, Keiser J: Isothermal microcalorimetry to study drugs against Schistosoma mansoni. J Clin Microbiol 2011, 49:1217-1225.
• [16]Ingram K, Ellis W, Keiser J: Antischistosomal activities of mefloquine-related arylmethanols. Antimicrob Agents Chemother 2012, 56:3207-3215.
• [17]O’Brien J, Wilson I, Orton T, Pognan F: Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000, 267:5421-5426.
• [18]Doenhoff MJ, Cioli D, Utzinger J: Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008, 21:659-667.
• [19]Théron A, Mouahid G, Moné H: Schistosoma mansoni: cercarial shedding patterns from a mixed infection of Biomphalaria glabrata with two (early and late) chronobiological variants. J Parasitol Res 1997, 83:356-358.
• [20]Théron A, Pages JR: Analysis and comparison of cercarial emergence rhythms of Schistosoma haematobium, S. intercalatum, S. bovis and their hybrid progeny. Int J Parasitol 1990, 20:193-197.
• [21]Dawood IK, Chu KY: Cercarial production from Biomphalaria alexandrina infected with Schistosoma mansoni. Bull World Health Organ 1970, 42:569-574.
• [22]Salafsky B, Fusco AC, Whitley K, Nowicki D, Ellenberger B: Schistosoma mansoni: analysis of cercarial transformation methods. Exp Parasitol 1988, 67:116-127.
• [23]Hoffmann KF, Peak E: Cross-disciplinary approaches for measuring parasitic helminth viability and phenotype. An Acad Bras Cienc 2011, 83:649-662.
• [24]Ndao M: Diagnosis of Parasitic Diseases: Old and new approaches. Interdiscip Perspect Infect Dis 2009, 2009:278246.
• [25]Denham DA, Holdsworth RJ: The effect of metrifonate in vitro on Schistosoma haematobium and S. mansoni adults. Trans R Soc Trop Med Hyg 1971, 65:696.
• [26]Pica-Mattoccia L, Novi A, Cioli D: Enzymatic basis for the lack of oxamniquine activity in Schistosoma haematobium infections. Parasitol Res 1997, 83:687-689.
• [27]Rollinson D: A wake up call for urinary schistosomiasis: reconciling research effort with public health importance. Parasitology 2009, 136:1593-1610.